On November 26th (Thanksgiving Day eve in the USA), the US Food and Drug Administration (FDA) released a fistful of Establishment Inspection Reports (EIRs) and Inspectional Observational reports (FDA Form 483s) pertaining to inspections carried out between 2022 and 2025 at ByHeart production and packaging locations in Reading (Pennsylvania), Portland (Oregon), and Allerton (Iowa).

This document dump did not include any preliminary information relating to the current investigation triggered by an outbreak of infant botulism in newborns and infants who were fed ByHeart Whole Nutrition Infant Formula.

Nevertheless, the EIRs provide a window into the company’s operations and its approach to food safety.

New kid on the block

In 2019, after some three years of developing and refining their formula, ByHeart acquired their manufacturing facility in Reading and according to the company’s website, “…upgraded it to provide the very best conditions…” for producing powdered infant formula base.

Reading, PA

Although the facility sailed through a FDA inspection in May/June 2022 with a classification of No Action Indicated, conditions in Reading were far from perfect.

At the completion of the May/June 2022 inspection, FDA investigators noted several “items for discussion,” including:

• Incomplete environmental swabbing follow-up after a water leak from the roof that occurred;
• The firm did not test for the same pathogens after the water event as they do during their Environmental Monitoring Program;
• Production records revealed multiple cross-outs and corrections by the Quality department for incorrect lot codes of ingredients, job number, customer lot number, etc., and at times, the handwriting was too small to interpret;
• Environmental swabbing recording form was not always fully completed; and
• Drying time was not being documented on the Infant Formula Dryer Processing Report.

Management agreed to address all of the items; however, some issues remained when the FDA returned on December 21, 2022.

During that inspection, which was closed out on February 17, 2023, FDA investigators learned that the Reading location was notified in October 2022 that Cronobacter sakazakii had been found in a finished product for which Reading provided the base formula. Reading conducted a “root cause analysis” and concluded that the positive test was the result of an error on the part of the 3rd party contract lab.

The lab rebutted Reading’s contention, with a report that concluded “Laboratory error was not found or supported.”

This was not the only incident of Cronobacter sakazakii in the company’s product or the production environment. Nor was it the only issue highlighted during the FDA inspection. The outcome of the inspection was classified as Official Action Indicated.

On August 30, 2023, the FDA issued a Warning Letter to ByHeart citing “…significant violations of Title 21, Code of Federal Regulations, Part 106 (21 C.F.R. Part 106), Infant Formula Requirements Pertaining to Current Good Manufacturing Practice, Quality Control Procedures, Quality Factors, Records and Reports, and Notifications (“the Infant Formula Rule”).”

In September 2023, the company ceased production at its Reading facility and has not yet resumed operations.

The next inspection took place from December 11, 2023 to January 19, 2024, while the plant was shut down and consisted, for the most part, of a review of records.

Once again, the FDA investigators identified a list of violations, including mold contamination in a water tank, a history of multiple roof leaks and water leaks, significant insect activity, and inadequate or improper temperature monitoring and documentation, among others. The FDA issued a Form 483 list of Objectionable Conditions and the inspection was classified as Official Action Indicated.

Portland, OR

ByHeart purchased the Portland blending and packaging facility in January 2023.

Until December 1, 2023, Portland received powdered infant formula base from both Reading and Allerton, blended lactoferrin into the base powder, and filled the complete infant formula powder into cans. After that date, all base poiwder was supplied by Allerton.

The FDA conducted its first post-purchase inspection of the Portland location in April 2024, at which time the facility was in a scheduled shutdown. The inspection included a review of seven production batch records, as well as of documents pertaining to environmental monitoring, sanitation, water events, microbiological and nutrient testing, and so forth. No significant issues were recorded, and the inspection was classified as No Action Indicated.

In March 2025, the FDA carried out a more thorough inspection of the plant’s operations. Part of the inspection included a follow-up to consumer complaints received by the FDA and/or ByHeart since the previous inspection. Among these were ten complaints relating to gastrointestinal illnesses, including:

• Eight Salmonella
• One E. coli
• One Campylobacter

In every case, the firm’s investigation (based solely on a review of records) concluded there was no evidence that the microbe had come from in the infant formula batch, and no further action was taken.

Allerton, IA

ByHeart announced its acquisition of the Allerton facility from Dairy Farmers of America in January 2023. In doing so, it purchased a peck of trouble.

The final FDA inspection (conducted in May-June 2022) of Allerton prior to ByHeart’s purchase highlighted problems with cleaning and sanitation, presence of Cronobacter sakazakii in the environment around a spray dryer, numerous roof leaks into the processing areas, a finding of Cronobacter in a batch of finished product, temperature chart calibration issues, and flow meter calibration issues.

The 2022 inspection was classified Voluntary Action Indicated. In June 2023, the FDA conducted a follow-up inspection in order to review the new owner’s corrective actions. Some of the issues were verified as corrected, whereas others would have to wait until the company began manufacturing. During the final meeting with Allerton’s management team, the FDA investigator stressed that “…continuous improvement and routine maintenance to [the] aging facility would be vital to prevent contamination of the powdered infant formula supply.”

In January 2024, with the facility now in full operation, the FDA team documented multiple improvements to the physical plant, although inspection of the internal surfaces of a spray dryer revealed multiple cracks, areas of denting, and weld spatter. The inspection was classified as No Action Indicated.

One year later, Allerton’s performance had deteriorated. An inspection conducted in February 2025 noted that the company had twelve confirmed Cronobacter sakazakii in environmetal samples from January 2024 to February 2025. In addition, the inspectors observed rusty surfaces in multiple on the floor of one of the dryer levels, documented that epoxied surfaces were peeling, and noted that the floor under one of the air duct had rust.

On reviewing the Allerton pest management program, inspectors documented multiple instances of rodent activity. Additionally, FDA inspectors took exception to the company’s approval and release for use on more than one occasion of an ingredient that was part of a shipment showing evidence of rodent activity, including rodent excreta and torn bags.

During the closeout discussion, Kathleen Whitesell, the Senior Director of Food Safety, who oversees food safety and quality for all three ByHeart locations, insisted that the rodent infestation did not represent a food safety concern, due to the existence of a ‘kill step.’ In response, the FDA investigators reminded the firm that “…although there may be a ‘kill step,’ it is not a good practice to add to the microbial load…” prior to that step.

The February 2025 inspection was classified Voluntary Action Indicated.

The take-aways

Old facilities are maintenance-intensive

ByHeart’s facility in Reading was built in 1993. The company purchased it from Sensory Effects Powder Systems in 2019.

The Allerton plant was purchased from Dairy Farmers of America in 2023 and was described by FDA investigators as an “aging facility” that would require “continuous improvement and routine maintenance.”

Both of these facilities have undergone prolonged production shutdowns for maintenance and repair since ByHeart acquired them.

FDA inspections are not created equal

Inspections conducted during production shutdowns are a waste of time. Very little is proved by a “review of records” other than the company’s diligence in record-keeping.

The June 2023 inspection of Allerton did not uncover the problems regarding cracks on the interior surface of the spray dryer. Yet a further inspection, conducted just six months later, found multiple issues of cracks and dents inside the dryer. What changed? The 2023 inspection was conducted during a production shutdown and was far less detailed than the 2024 inspection.

The level of scrutiny adhered to by FDA investigators during an inspection also is determined by the reason for the inspection. Routine surveillance inspections are less intensive than inspections conducted “for cause” (e.g., as part of a foodborne disease outbreak investigation). A clean inspection report (one classified as No Action Indicated) is no guarantee that everything is under control. Rather, it means that no problems were uncovered at the level of scrutiny practiced by the FDA inspector(s) during that inspection.

Could the botulism problem have been prevented?

All of the inspection reports released by the FDA for the three ByHeart locations predate the investigation into the ongoing infant botulism outbreak.

While it is impossible to draw conclusions based on the information available so far, one thing is clear.

Both the Reading and the Allerton production facilities were experiencing deteriorating sanitation, pest control, and microbiological safety conditions during the 2023-2025 period.

Corporate attitude is fundamental to food safety

ByHeart’s attitude to food safety and quality assurance was reflected in the statement of the company’s Senior Director of Food Safety (now Vice President, Quality), who expressed the view that evidence of rodent infestation in the ingredients was not a food safety concern as long as there was a ‘kill step’ in the production process to eliminate microbes.

---

Interested in learning more about food safety and the history of foodborne disease outbreaks and investigations?

Click on the link to listen to a short excerpt, then follow the buy links to add a digital, print or audio copy to your personal library.

In an update posted on the company’s website, ByHeart is warning its customers that “…all ByHeart formula across all product lots…” may be contaminated with Clostridium botulinum.

The warning comes after the company’s third-party testing lab (IEH IEH Laboratories & Consulting Group) found Clostridium botulinum in three out of three production lots. Five out of 36 samples tested were positive for the pathogen.

On November 11, 2025, ByHeart expanded an earlier product recall include all batches of ByHeart Whole Nutrition Infant Formula cans and Anywhere Pack™. The recalled products were distributed on-line and nationwide across the United States, including Guam and Puerto Rico.

Information provided to the FDA by Amazon indicates that a limited quantity of recalled products also were distributed to Argentina, Brazil, Brunei, Canada, Chile, China, Colombia, Ecuador, Egypt, Hong Kong, Israel, Jamaica, Japan, Republic of Korea, Peru, Philippines, Romania, Singapore, South Africa, Thailand, and Virgin Islands.

As of November 19, 2025, the CDC reported 31 confirmed and suspected cases of infant botulism associated with consumption of ByHeart powdered infant formula. The affected infants range in age from 16 to 200 days.

In its communication to parents and caregivers, ByHeart has issued the following advice and information:

We want to reaffirm the critical direction for parents and caregivers to stop using ByHeart formula immediately. We continue to strongly recommend monitoring for symptoms of infant botulism and to contact a medical professional immediately if your child develops symptoms.

• According to the American Academy of Pediatrics, the sign of Infant Botulism appears at an estimated 3 to 30 days from the time of consumption of the Clostridium botulinum bacteria.
• Symptoms often begin with constipation followed by difficulty feeding (sucking and swallowing), a weak and altered cry, diminished facial expression, droopy eyelids, loss of head control, and lethargy. 

---

Interested in learning more about food safety and the history of foodborne disease outbreaks and investigations?

Click on the link to listen to a short excerpt, then follow the buy links to add a digital, print or audio copy to your personal library.